Journals / Türk Geriatri Dergisi / 2014 / Cilt: 17 - Sayı: 2

KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİ OLAN YAŞLI HASTALARDA PROGNOSTİK FAKTÖRLERİN SAĞKALIMA ETKİSİ

EFFECT OF PROGNOSTIC FACTORS ON SURVIVAL IN ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CANCER

Pages
113–118
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mortality risk wasanalyzed using the multivariate Cox regression model including all the significant variables in theunivariate analysis.Results: Overall survival estimated by Kaplan-Meier test was 11.2 [95% confidence interval(7.55-14.85)] months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: More than half of newly diagnosed non-small cell lung cancer cases are patients aged more than 65 years and therefore, it is an important health problem in elderly population.
📊
Key Findings & Data:In this study, we aimed to investigate effect of various the prognostic factors on survival innon-small cell lung cancer patients aged more than 65 years.Materials and Method: Ninety-seven non-small cell lung cancer patients aged >=65 years were included in this study.
💡
Conclusion & Impact:Mortality risk wasanalyzed using the multivariate Cox regression model including all the significant variables in theunivariate analysis.Results: Overall survival estimated by Kaplan-Meier test was 11.2 [95% confidence interval(7.55-14.85)] months.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: More than half of newly diagnosed non-small cell lung cancer cases are patients aged more than 65 years and therefore, it is an important health problem in elderly population. In this study, we aimed to investigate effect of various the prognostic factors on survival innon-small cell lung cancer patients aged more than 65 years.Materials and Method: Ninety-seven non-small cell lung cancer patients aged >=65 years were included in this study. Performance status was assessed as Eastern Cooperative Oncology Group 0-1 and 2-3. Lower than 12.0 (x 109/L) or higher than the value of white blood cell count were classified as normal or higher, respectively. Similarly, lower than 400 (x 109/L) or higher thanthe value of platelet count were classified as normal or higher, respectively. Mortality risk wasanalyzed using the multivariate Cox regression model including all the significant variables in theunivariate analysis.Results: Overall survival estimated by Kaplan-Meier test was 11.2 [95% confidence interval(7.55-14.85)] months. In univariate analysis, performance status, stage, white blood cell and platelet counts significantly affected overall survival (p

Özet

Giriş: Yeni tanı alan küçük hücreli dışı akciğer kanseri olan olguların yarısından fazlası 65 yaşüstü olgulardır ve bundan dolayı yaşlı nüfus için önemli bir sağlık sorunudur. Bu çalışmada biz küçük hücreli dışı akciğer kanseri olan 65 yaş ve üstü yaşlı hastalarda sağkalım üzerine çeşitli prognostik faktörlerin etkisini araştırmayı planladık.Gereç ve Yöntem: Histopatolojik olarak küçük hücreli dışı akciğer kanseri tanısı konan 65yaş ve üstü 97 olgu bu çalışmaya dahil edildi. Performans durumu, Eastern Cooperative OncologyGroup 0-1 ve 2-3 olarak iki grupta ele alındı. Beyaz küre sayısı 12.0 (x 109/L)'den düşük ise normal, bu değerden fazla ise yüksek olarak sınıflandı. Benzer olarak, trombosit sayısı 400 (x109/L)'den düşük ise normal, bu değerden fazla ise yüksek olarak sınıflandı. Mortalite riski, tekdeğişkenli analizde anlamlı olan tüm değişkenlerin dahil edildiği çok değişkenli Cox regresyon modeli kullanılarak analiz edildi.Bulgular: Kaplan-Meier testi ile saptanan genel sağkalım süresi 11,2 [%95 Güven Aralığı(7.55-14.85)] aydı. Tek değişken analizde performans skoru, evre, beyaz küre ve trombosit sayısı genel sağkalımı anlamlı olarak etkiliyordu (sırasıyla p

🔖

Cite This Article

KURTUL, N., ÜNAL, D., GÖKSU, S. S., OUZ, A., TAŞDEMİR, A., ORHAN, O., EROLU, C., KAPLAN, B. (2022). KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİ OLAN YAŞLI HASTALARDA PROGNOSTİK FAKTÖRLERİN SAĞKALIMA ETKİSİ. Türk Geriatri Dergisi, Cilt: 17 - Sayı: 2, 113–118. https://ajindex.com/articles/623868

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Parkin DM. Global cancer statistics in the year 2000. LancetOncol 2001
  2. 2(9):533-43. (PMID:11905707). 2.Govindan R, Page N, Morgensztern D, et al. Changingepidemiology of small-cell lung cancer in the United States overthe last 30 years: Analysis of the surveillance, epidemiologic,and end results database. J Clin Oncol 2006
  3. 24(28):4539-44.(PMID:17008692). 3.Pallis AG, Gridelli C, van Meerbeeck JP, et al. EORTC ElderlyTask Force and Lung Cancer Group and International Societyfor Geriatric Oncology (SIOG) experts’ opinion for thetreatment of non-small-cell lung cancer in an elderlypopulation. Ann Oncol 2010
  4. 21(4):692-706.(PMID:19717538). 4.Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly.Eur J Cancer 1997
  5. 33(14):2313-4. (PMID:9616273). 5.Kefeli U, Kaya S, Ustaalioglu BO, et al. Prognostic factors inelderly patients with non-small cell lung cancer: A two-centerexperience. Med Oncol 2011
  6. 28(3):661- 6. (PMID:20354816).6.Mountain CF. Revisions in the international system for staginglung cancer. Chest 1997
  7. 111(6):1710-7. (PMID:9187198). 7.Oken MM, Creech RH, Tormey DC, et al. Toxicity andresponse criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol 1982
  8. 5(6):649-55. (PMID:7165009). 8.Nutritional anaemias. Report of a WHO scientific group.World Health Organ Tech Rep Ser 1968
  9. (PMID:4975372). 9.Arslan C, Kilickap S, Dede DS, et al. Frequency of cancer typesin patients aged 65 and older: Results from cancer registrydatabase of Hacettepe University Hospitals. Turk J Geriatr2011
  10. 14(3):187-92. (in Turkish). 10. Yu D, Liu B, Zhang L, Du K. Platelet count predicts prognosisin operable non-small cell lung cancer. Exp Ther Med2013
  11. 5(5):1351-4. (PMID:23737877). 11. Sasaki K, Kawai K, Tsuno NH, et al. Impact of preoperativethrombocytosis on the survival of patients with primarycolorectal cancer. World J Surg. 2012
  12. 36(1):192-200.(PMID:22045447). 12. Stone RL, Nick AM, McNeish IA, et al. Paraneoplasticthrombocytosis in ovarian cancer. N Engl J Med2012
  13. 366(7):610-8. (PMID:22335738). 13. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, et al.Platelet to lymphocyte ratio as a prognostic factor for epithelialovarian cancer. J Gynecol Oncol 2012
  14. 23(4):265-73.(PMID:23094130). 14. Dineen SP, Roland CL, Toombs JE, et al. The acellular fractionof stored platelets promotes tumor cell invasion. J Surg Res2009
  15. 153(1):132-7. (PMID:18541268). 15. Tol J, Punt CJ. Monoclonal antibodies in the treatment ofmetastatic colorectal cancer: Areview. Clin The